We are thrilled to highlight our ongoing partnership with Inotrem, an advanced clinical-stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes. Inotrem focuses on targeting the TREM-1 pathway, an innate immune amplifier, to restore balance in inflammatory diseases

Their lead product, nangibotide, is a first-in-class TREM-1 inhibitor currently in development for severe conditions such as septic shock and COVID-19. Additionally, Inotrem is advancing INO-02, a long-acting therapeutic approach for Inflammatory Bowel Disease (IBD), with support from the Crohn's & Colitis Foundation.

Here's what Delphine Joyeux, Regulatory Affairs and Quality Director at Inotrem, had to say about collaborating with INITS:

"INITS has been supporting me in all my Quality activities for 3 years now, always with professionalism. The team at INITS is very experienced and reactive. It is a real pleasure to work with them!"

At INITS, we are committed to providing expert, responsive support to our clients, ensuring that their quality and regulatory needs are met with the highest standards. Our team's dedication and extensive experience allow us to tackle complex challenges and deliver tailored solutions that drive success.

Thank you, Inotrem, for trusting INITS as your partner in advancing life-changing therapies. We look forward to continuing this fruitful collaboration!

Find all our testimonials on our website: https://inits.fr/

#Partnership #Biotechnology #QualityAssurance #RegulatoryAffairs #Innovation #Biomanufacturing